SEARCH

SEARCH BY CITATION

References

  • 1
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 2
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958965.
  • 3
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha 2a and ribavirin combintion therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346355.
  • 4
    Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Eng J Med 2003; 342: 18781886.
  • 5
    Lee SS, Bain VG, Peltekian K, Krajden M, Yoshida EM, Deschenes M, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006; 23: 397408.
  • 6
    Kumar D, Wallington-Beddoe C, George J, Lin R, Samarasinghe D, Liddle C, et al. Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting. Med J Aus 2003; 178: 267271.
  • 7
    Gheorghe L, Grigorescu M, Iacob S, Damian D, Gheorghe C, Iacob R, et al. Effectiveness and tolerability of pegylated interferon α-2a and ribavirin combination therapy in Romainan patients with chronic hepatitis C: from clinical trials to clinical practice. Romanian J Gastroenterol 2005; 14: 109115.
  • 8
    Piai G, Scalice, Focareta R, Terracciano F, de Filippo FR, Forte G. From trials to a real hospital setting: effectiveness of pegylated interferon-α-2b/ribavirin combination therapy for naïve chronic hepatitis C patients. Dig Dis Sci 2006; 51: 16191626.
  • 9
    Borroni G, Andreoletti M, Casiraghi MA, Ceriani R, Guerzoni P, Omazzi B, et al. Effectiveness of pegylated interferon/ribavirin combination in “real world” patients with chronic hepatitis C virus (HCV) infection. Aliment Pharmacol Ther 2008; 27: 790797.
  • 10
    Shehab TM, Fontana RJ, Oberhelman K, Marrero JA, Su GL, Lok AS. Effectiveness of interferon α-2b and ribavirin combination therapy in the treatment of naïve chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol 2004; 2: 425431.
  • 11
    Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004; 117: 163168.
  • 12
    Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterol 2006; 131: 470477.
  • 13
    Shiffman ML, Mihas AA, Millwala F, Sterling RK, Luketic VA, Stravitz RT, et al. Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol 2007; 102: 761766.
    Direct Link:
  • 14
    Srivastava S, Bertagnolli M, Lewis JH. Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic. J Natl Med Assoc 2005; 97: 17031707.
  • 15
    Gaglio PJ, Rodriguez-Torres M, Herring R, Anand B, Box T, Rabinovitz M, et al. Racial differences in response rates to consensus interferon in HCV infected patients naïve to previous therapy. J Clin Gastroenterol 2004; 38: 599604.
  • 16
    Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, et. Al. Peginteferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009; 360: 257267.
  • 17
    Iacobellis A, Ippolito A, Andriulli A. Antiviral therapy I hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J Gastroenterology 2008; 42: 64676472.
  • 18
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705714.
  • 19
    Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. HEPATOLOGY 2003; 37: 13431350.
  • 20
    Muir A, Bornstein J, Killenberg P, Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment f chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 22652271.
  • 21
    Jeffers L, Cassidy W, Howell C, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. HEPATOLOGY 2004; 39: 17021708.
  • 22
    Yu S, Douglass JM, Qualls C, Arora S, Dunkelberg JC. Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in Hispanics compared to non-Hispanic whites. Am J Gastroenterol 2009; 104: 16861692.
  • 23
    Cheung RC, Currie S, Shen H, Ho SB, Bini EJ, Anand BS, et al. Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 2005; 100: 21862193.
    Direct Link: